

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 June 2025 (05.06.2025)



(10) International Publication Number
WO 2025/113841 A1

(51) International Patent Classification:

A61K 31/4995 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2024/075992

(22) International Filing Date:

17 September 2024 (17.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23383234.4 30 November 2023 (30.11.2023) EP

(71) Applicant: PHARMA MAR, S.A. [ES/ES]; Polígono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, E-28770 Madrid (ES).

(72) Inventors: AVILES MARIN, Pablo Manuel; c/o Pharma Mar, S.A., Polígono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, E-28770 Madrid (ES). GUILLEN NAVARRO, Maria Jose; c/o Pharma Mar, S.A., Polígono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, E-28770 Madrid (ES). COIN, Frédéric; c/o INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), 101, rue de Tolbiac, 75013 Paris (FR). EGLY, Jean Marc; c/o INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), 101, rue de Tolbiac, 75013 Paris (FR).

(74) Agent: GURNEY, Steven; Evolve Intellectual Property Limited, 9 Hills Road, Cambridge, Cambridgeshire CB2 1GE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: LURBINECTEDIN, ECUBECTEDIN AND A RELATED COMPOUND FOR USE IN THE TREATMENT OF SKIN CANCERS




Figure 2

(57) Abstract: The present invention relates to the therapeutic treatment of skin cancer, particularly melanoma by using lurbinectedin, PM14 (ecubectedin) and Compound IA.

WO 2025/113841 A1